ITCA 650: Phase III data

Top-line data from the double-blind, international Phase III FREEDOM-CVO cardiovascular outcomes trial in >4000 Type II diabetics showed that once-daily 60 ug ITCA 650 plus standard of care

Read the full 284 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE